Azitra, INC

Azitra, Inc. announced its Q2 2026 financial results, highlighting preclinical data for ATR-COSF, continued enrollment in ATR-04 trials, and expansion into recombinant protein initiatives.

Azitra, Inc. reported promising ex vivo human skin tissue study results for its ATR-COSF program, demonstrating increased distribution and anti-wrinkle effects.

Azitra, Inc. announces a strategic reorientation towards cosmetic ingredients and biotechnology products, leveraging its microbial genetic engineering platform and recent financing.

Azitra, Inc. announced the results of its reconvened 2026 annual meeting of stockholders, where key proposals including an increase in authorized common stock were approved.

Azitra, Inc. has adjourned its 2026 Annual Meeting of Stockholders to June 15, 2026, due to an insufficient number of shares present to constitute a quorum.

Azitra, Inc. has announced the adjournment of its 2026 Annual Meeting of Stockholders to June 15, 2026, due to a minor administrative delay in mailing proxy materials.

Azitra, Inc. files its Q2 2026 10-Q, detailing continued operational losses and efforts to regain NYSE listing compliance, alongside significant financing activities.

Azitra, Inc. reported a significant increase in net loss and received a NYSE American delisting notice, raising substantial doubt about its ability to continue as a going concern.

Azitra, Inc. reported increased net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and new financing efforts.

Azitra Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for ATR-12 and ATR-04 while acknowledging substantial doubt about its ability to continue as a going concern.

Azitra Inc. announced its third quarter 2024 financial results, highlighting advancements in clinical trials for its lead product candidates and ongoing research and development efforts.

Azitra Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2024, highlighting ongoing clinical trial progress and strategic partnerships.

Azitra, Inc. reported increased net losses and a significant accumulated deficit for 2025, raising substantial doubt about its ability to continue as a going concern, despite progress in early-stage clinical trials and recent capital raises.

Azitra, Inc.'s 10-K filing summarizes the company's financial results for fiscal year 2024 and provides an update on its clinical development programs in precision dermatology.

Azitra, Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Azitra Inc.'s 10-K filing details the company's capital structure, ongoing clinical programs, and strategic focus on precision dermatology.

Azitra, Inc. insider Francisco D. Salva reported a conversion of Series A Preferred Stock into common stock on June 16, 2026.

Azitra, Inc. Chief Financial Officer Norm Staskey was granted 35,524 stock options as part of a compensation package.

Azitra, Inc. CEO Francisco D. Salva was granted 220,879 stock options as part of a standard equity compensation arrangement.

Azitra, Inc. Chief Operating Officer Travis Whitfill was granted 64,300 stock options with an exercise price of $0.2127.

Azitra's President and CEO, Francisco D. Salva, acquired Series A Preferred Stock and Series B and C Warrants, contingent on future stockholder approvals and study results.

Azitra, Inc.'s Chief Operating Officer and Director, Travis Whitfill, was granted 23,724 stock options with an exercise price of $0.2968.

Azitra, Inc. seeks shareholder approval for a massive authorized share increase, reverse stock splits, and ratification of recent private placement financing.

Azitra, Inc. urges stockholders to approve a share issuance exceeding 19.99% to Alumni Capital LP, crucial for securing an additional $1.5 million in funding and avoiding severe operational risks.

Azitra, Inc. has issued a supplement to its proxy statement, revising the voting standard for a proposal to double its authorized common stock from 100 million to 200 million shares, now requiring a majority of votes cast instead of outstanding shares.

Azitra, Inc. is holding its 2025 Annual Meeting to seek stockholder approval for key proposals including increasing authorized common stock to 200 million shares and approving an equity line of credit with Alumni Capital LP for up to $20 million, citing insufficient cash to fund operations for the next twelve months.

Azitra, Inc. has filed a definitive proxy statement with the SEC.

Azitra, Inc. is holding a special meeting of stockholders to vote on a reverse stock split proposal aimed at maintaining its listing on the NYSE American.

Azitra, Inc. has filed an S-1 registration statement for the resale of up to 255,699,381 shares of its common stock by selling stockholders, following a private placement.

Azitra, Inc. files an S-1 registration statement for the resale of over 51 million shares by selling stockholders, including those from recent capital raises, while facing NYSE American minimum equity non-compliance.

Azitra, an early-stage biopharmaceutical company, announced a best-efforts public offering of common stock and pre-funded warrants to raise up to $10 million for its precision dermatology programs, following a recent 1-for-6.66 reverse stock split and a 'going concern' warning.

Biopharmaceutical company Azitra, Inc. filed an S-1 registration statement to allow selling stockholders to resell up to 2.2 million shares underlying warrants, while acknowledging substantial doubt about its ability to continue as a going concern and a significant drop in its stock price since its 2023 IPO.

Azitra Inc. has filed a registration statement for the potential resale of up to 66,889,632 shares of common stock and 6,688,963 shares underlying warrants by Alumni Capital LP, aiming to raise up to $22.6 million for working capital and general corporate purposes.

Azitra, Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its S-1 registration statement for a public offering of up to 3,115,265 units, each consisting of one share of common stock or one pre-funded warrant and two Class A warrants, aiming to raise up to $10 million.

Azitra, Inc. CEO Francisco D. Salva reports beneficial ownership of 9.99% of the company's common stock following a preferred stock conversion.

Nantahala Capital Management, LLC, along with its principals Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 9.99% of Azitra, Inc.'s common stock as of June 30, 2026.

Dauntless Investment Group, LLC has filed a Schedule 13G reporting a 9.6% beneficial ownership stake in Azitra, Inc. common stock.

Alumni Capital LP, along with its general partner and controlling person, reported a 9.99% beneficial ownership stake in Azitra, Inc. common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has amended its Schedule 13G filing, reporting a reduced beneficial ownership of 2.6% in Azitra, Inc.

Alumni Capital LP, along with its general partner and manager, disclosed a beneficial ownership of 9.99% in Azitra, Inc. common stock through a Schedule 13G filing.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 6.48% beneficial ownership stake in Azitra, Inc.'s Class A Common Stock, primarily through warrants.